Volume 12, Issue 4 (Jul-Aug 2018)                   mljgoums 2018, 12(4): 1-6 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Asadzadeh Aghdaei H, Pezeshkian Z, Abdollahpour-Alitappeh M, Nazemalhosseini Mojarad E, Zali M R. The Role of Angiogenesis in Colorectal Polyps and Cancer, a Review. mljgoums. 2018; 12 (4) :1-6
URL: http://goums.ac.ir/mljgoums/article-1-1093-en.html
1- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Larestan University of Medical Sciences, Larestan, Iran
3- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran , ehsanmojarad@gmail.com
4- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (2719 Views)
ABSTRACT
          Colorectal cancer remains a leading cause of morbidity and mortality worldwide. Most colorectal cancers begin as a growth of tissue called a polyp, some types of which can change into cancer over the course of several years. Angiogenesis, the formation of new blood vessels, is known to play a key role in the initiation, growth and progression of polyp and colorectal cancer. In this review, we discuss the mechanisms involved in colorectal cancer and polyp angiogenesis.
          Keywords: Colorectal Neoplasms, Polyps, Angiogenesis
Full-Text [PDF 465 kb]   (488 Downloads)    
Type of Study: Review Article |
Received: 2018/06/3 | Accepted: 2018/06/3 | Published: 2018/06/3 | ePublished: 2018/06/3

References
1. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am. 2008; 37: 1-24. [DOI:10.1016/j.gtc.2007.12.002]
2. Safaee A, Moghimi-Dehkordi B, Fatemi SR, Ghiasi S, Nemati-Malek F, MR Zali. Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev. 2010; 11(5): 1373-5.
3. Shussman N, Steven DW. Colorectal polyps and polyposis syndromes. Gastroenterol Rep. 2014; 2(1): 1-15. [DOI:10.1093/gastro/got041]
4. Haggar FA, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin Colon Rectal Surg. 2009; 22(4): 191-7. [DOI:10.1055/s-0029-1242458]
5. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiology Biomarkers Prev. 2008; 18(6): 1688-94. [DOI:10.1158/1055-9965.EPI-09-0090]
6. Leslie A, Carey FA, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89(7): 845-60. [DOI:10.1046/j.1365-2168.2002.02120.x]
7. NL B, Kalkbrenner KA, Merchea A, Dozois EJ, Landmann RG, De Petris G, et al. Colectomy for endoscopically unresectable polyps: how often is it cancer?. Dis Colon Rectum. 2012; 55(11): 1111-6. [DOI:10.1097/DCR.0b013e3182695115]
9. Liljegren A, Lindblom A, Rotstein S, Nilsson B, Rubio C, Jaramillo E. Prevalence and incidence of hyperplastic polyps and adenomas in familial colorectal cancer: correlation between the two types of colon polyps. Gut. 2003; 52(8): 1140-7. [DOI:10.1136/gut.52.8.1140]
10. Sam Al-Sohaily, Andrew Biankin, Rupert Leong, Maija Kohonen-Corish, Warusavitarne J. Molecular pathways in colorectal cancer. JGH. 2012; 27(9): 1423-31. [DOI:10.1111/j.1440-1746.2012.07200.x]
11. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350-6. [DOI:10.1038/nm.3967]
12. Mundade R, Imperiale TF, Prabhu L, Loehrer PJ, Lu T. Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 2014; 1(6): 400-6. [DOI:10.18632/oncoscience.59]
13. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138(6): 2059-72. [DOI:10.1053/j.gastro.2009.12.065]
14. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic Alterations in Colorectal Cancer. Gastrointest Cancer Res. 2012; 5(1): 19-27.
15. Nazemalhosseini Mojarad E, Kuppen PJK, Asadzadeh Aghdaei H, MR Zali. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterology and Hepatology From Bed to Bench. 2013; 6(3): 120-8.
16. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003; 47(3): 149-61.
17. Johnson KE, Wilgus TA. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv Wound Care. 2014; 3(10): 647-61. [DOI:10.1089/wound.2013.0517]
18. Masoumi Moghaddam, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012; 31(1-2): 143-62. [DOI:10.1007/s10555-011-9337-5]
19. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013; 10(2): 55-67.
20. Pang RW, Kojiro M. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006; 2(2): 97-108. [DOI:10.2147/vhrm.2006.2.2.97]
21. Ucuzian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. J Burn Care Res. 2010; 31(1): 158-75. [DOI:10.1097/BCR.0b013e3181c7ed82]
22. Siekmann AF, Lawson ND. Notch signalling and the regulation of angiogenesis. Cell Adh Migr. 2007; 1(2): 104-6. [DOI:10.4161/cam.1.2.4488]
23. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011; 2(12): 1097-105. [DOI:10.1177/1947601911423031]
24. Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res. 2007; 27(5A): 3245-50.
25. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8): 579-91. [DOI:10.1038/nrc2403]
26. Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012; 5: 63. [DOI:10.1186/1756-8722-5-63]
27. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013; 328(1): 18-26. [DOI:10.1016/j.canlet.2012.08.018]
28. Ahmad SA, Liu W, Jung YD, Fan F, Reinmuth N, Ellis LM, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma . A possible mechanism for the initiation of angiogenesis. Cancer. 2001; 92: 1138 –43. https://doi.org/10.1002/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L [DOI:10.1002/1097-0142(20010901)92:53.0.CO;2-L]
29. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999; 103(3): 341-5. [DOI:10.1172/JCI4891]
30. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin 2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001; 61(5): 2145-53.
31. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer. 2000; 29(1): 11-22. [DOI:10.1016/S0169-5002(00)00118-5]
32. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. AmJ Pathol. 1999; 155(6): 1967-76. [DOI:10.1016/S0002-9440(10)65515-0]
33. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998; 153(5): 1459-66. [DOI:10.1016/S0002-9440(10)65733-1]
34. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1998; 284(5422): 1994-8. [DOI:10.1126/science.284.5422.1994]
35. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res. 2001; 61(16): 6248-54.
36. Huang H BA, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010; 10(8): 575-85. [DOI:10.1038/nrc2894]
37. Kofler NM, Shawber CJ, Kangsamaksin T, Reed HO, Galatioto J, Kitajewski J. Notch Signaling in Developmental and Tumor Angiogenesis. Genes Cancer. 2011; 2(12): 1106-16. [DOI:10.1177/1947601911423030]
38. Siekmann AF, Lawson ND. Notch Signalling and the Regulation of Angiogenesis. Cell Adh Migr. 2007; 1(2): 104-6. [DOI:10.4161/cam.1.2.4488]
39. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003; 200(2): 183-94. [DOI:10.1002/path.1339]
40. Taba M, Nakayama T, Naito S, Mihara Y, Miura S, Naruke Y, et al. Differential Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in the Sequence of Hyperplastic Polyp, Serrated Adenoma and Adenocarcinoma of Colorectum. Acta Med. 2008; 53(4): 85-8.
41. Pezeshkian Z, Forouzesh F, Peyravian N, Yaghoob-Taleghani M, Asadzadeh-Aghdaei H, Zali MR, et al. Clinicopathological correlations of VEGF-A and MMP-7 genes expression in different types of colorectal adenoma polyps. WCRJ. 2017; 4(4): e978.
42. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009; 106(15): 6152-7. [DOI:10.1073/pnas.0813061106]
43. WC Pang R TPR. Clinical Implications of Angiogenesis in Cancers. Vasc Health Risk Manag. 2006; 2(2): 97-108. [DOI:10.2147/vhrm.2006.2.2.97]
44. Sang Hun Lee, Dongjun Jeong, Yong-Seok Han, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015; 89(1): 1-8. [DOI:10.4174/astr.2015.89.1.1]
45. Ehsan NazemalhosseiniMojarad, Kuppen PJ. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer. IMT. 2013; 5(12): 1267-9.
46. Gaya A, V T. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012; 38(5): 484-93. [DOI:10.1016/j.ctrv.2011.12.008]
47. Ciombor KK, Berlin J. Aflibercept—a Decoy VEGF Receptor. Curr Oncol Rep. 2014; 16(2): 368. [DOI:10.1007/s11912-013-0368-7]
48. Al-Husein B1 AM, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012; 32(12): 1095-111. [DOI:10.1002/phar.1147]

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2007 All Rights Reserved | Medical Laboratory Journal